Jan 20, 2011 01:43 PM IST
Limited downside in Biocon, says Vivek Mavani, Vice President & Senior Portfolio Manager, Brics Securities.
- Jan 20, 2011 10:42 AM IST
Indian biotechnology firm Biocon has declared its results for the quarter ended December 2010. It has reported consolidated net profiit at Rs 101 crore as against Rs 80.9 crore, a growth of 24.85% on year-on-year basis.
- Jan 20, 2011 07:36 AM IST
Indian biotechnology firm Biocon is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax is expected go up by 15% to Rs 93 crore in Q3FY11 as against Rs 80.9 crore in same period of previous year.
- Jan 11, 2011 10:45 AM IST
Biocon on Tuesday said initial data from late-stage clinical trials on its experimental oral insulin drug for diabetes did not meet the desired results, but said it was committed to the global development of the drug.
- Jan 05, 2011 10:44 AM IST
Biocon can test Rs 445, says Amit Gupta of ICICI Securities.
- Jan 04, 2011 09:35 AM IST
The firm is looking at partnerships with global pharma majors as a ticket to hasten the launch of its biotech products
- Jan 03, 2011 07:41 PM IST
Ranjit Kapadia, Vice President-Institutional Research, HDFC Securities is positive on Biocon.
- Jan 03, 2011 10:59 AM IST
In an exclusive interview with CNBC-TV 18, Kiran Mazumdar Shaw, CMD of Biocon says that Clingene & Syngene to undergo transformation in the business model and would wait for a year before listing the IPO. She also expects Pfizer revenues in the next 24-36 months.